Bronchiolitis, Viral
Conditions
Brief summary
The purpose of this study is to more rigorously evaluate the response to a single bolus of magnesium sulfate in a population of patients with moderate to severe bronchiolitis. The primary outcome will be to evaluate the effect of this therapy on clinical respiratory status. Secondary outcomes of interest will include the incidence of adverse effects and safety profile of magnesium bolus use in this population.
Detailed description
This randomized placebo-controlled pilot study is designed to evaluate the above referenced outcomes. Study drug initiation will occur in the local pediatric intensive care unit in patients with a clinical diagnosis of bronchiolitis and whose parent/LAR consents for their participation. Our goal is to enroll and evaluate a total of 40 patients. Upon obtaining informed consent, the participant will receive an enrollment history and physical to include: baseline Modified Pulmonary Index Score (MPIS), blood pressure, vital signs, and epidemiologic data. The participant will then receive either a bolus of 50mg/kg Magnesium Sulfate (MgSO4) or normal saline as placebo medication over twenty minutes. Vital signs and MPIS will be monitored according to the study schedule, for a total of six hours. During the period of monitoring subjects will not receive additional bronchodilators unless otherwise deemed clinically necessary by the subject's attending physician. If administered, these will be recorded by investigative team.
Interventions
DRUGMagnesium Sulfate
Randomized to receive either magnesium sulfate or normal saline placebo.
Sponsors
University of Louisville
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Blinding will be done in the pharmacy using a pre-developed randomization table. Study medication, whether MgSO4 or placebo, will be prepared by a study pharmacist and sent to the nursing/clinical staff for administration labelled as "study drug". Unblinding, if clinically indicated, can be provided to the treatment team but it is not anticipated that this will be required.
Intervention model description
This is a randomized placebo-controlled pilot study with 1:1 randomization
Eligibility
Sex/Gender
ALL
Age
1 Months to 12 Months
Healthy volunteers
No
Inclusion criteria
* Infants under 12 months of age * Admitted to the pediatric intensive care unit * Moderate/severe bronchiolitis using MPIS * Less than 24 hours of admission to the PICU * Parent/LAR consents for infant to participate
Exclusion criteria
* Patients with the following conditions are ineligible: chronic lung disease, unrepaired congenital heart disease, and cyanotic heart disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the effect of this therapy on clinical respiratory status | 6 hours post bolus of medication versus placebo | MPIS will be used to follow respiratory status |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identify the incidence of adverse effects and safety profile of magnesium sulfate | 6 hours post bolus of medication versus placebo | Patients will be followed for any potential adverse events. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJohn W Berkenbosch, MD
University of Louisville
Outcome results
None listed